Ratio Review: Analyzing Verona Pharma Plc ADR (VRNA)’s Price-to-Cash and Price-to-Free Cash Flow

Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

After finishing at $15.50 in the prior trading day, Verona Pharma Plc ADR (NASDAQ: VRNA) closed at $14.69, down -5.23%. In other words, the price has decreased by -$5.23 from its previous closing price. On the day, 1.1 million shares were traded. VRNA stock price reached its highest trading level at $15.87 during the session, while it also had its lowest trading level at $14.5945.

Ratios:

Our goal is to gain a better understanding of VRNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 18.40 and its Current Ratio is at 18.40. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.22.

On August 26, 2022, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $31.Piper Sandler initiated its Overweight rating on August 26, 2022, with a $31 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 03 ’24 when Rickard Kathleen A. sold 36,248 shares for $1.96 per share. The transaction valued at 71,032 led to the insider holds 2,621,552 shares of the business.

Rickard Kathleen A. sold 36,248 shares of VRNA for $80,503 on Feb 05 ’24. The Chief Medical Officer now owns 2,731,624 shares after completing the transaction at $2.22 per share. On Nov 20 ’23, another insider, Edwards Martin, who serves as the Director of the company, bought 33,736 shares for $1.84 each. As a result, the insider paid 61,973 and bolstered with 144,800 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRNA now has a Market Capitalization of 1258480512 and an Enterprise Value of 9325115392.

Stock Price History:

The Beta on a monthly basis for VRNA is 0.46, which has changed by -0.31737918 over the last 52 weeks, in comparison to a change of 0.2586832 over the same period for the S&P500. Over the past 52 weeks, VRNA has reached a high of $23.07, while it has fallen to a 52-week low of $11.39. The 50-Day Moving Average of the stock is 2.58%, while the 200-Day Moving Average is calculated to be -6.95%.

Shares Statistics:

The stock has traded on average 672.26K shares per day over the past 3-months and 1227280 shares per day over the last 10 days, according to various share statistics. A total of 80.44M shares are outstanding, with a floating share count of 62.41M. Insiders hold about 23.03% of the company’s shares, while institutions hold 60.10% stake in the company. Shares short for VRNA as of 1715731200 were 5574905 with a Short Ratio of 8.92, compared to 1713139200 on 6067490. Therefore, it implies a Short% of Shares Outstanding of 5574905 and a Short% of Float of 7.180000000000001.

Most Popular